Phio Pharmaceuticals Files 8-K for Material Agreement
Ticker: PHIO · Form: 8-K · Filed: 2026-04-08T16:15:54-04:00
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Phio Pharma just signed a big deal, filing an 8-K to make it official.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on April 8, 2026, to report the entry into a material definitive agreement. The filing includes financial statements and exhibits related to this agreement. Specific details of the agreement, including parties involved and financial terms, are not elaborated in the provided text.
Why It Matters
This filing indicates a significant new contract or partnership for Phio Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant financial or operational implications, but the lack of specific details makes the exact risk level uncertain.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Filer of the 8-K report
- 0001533040 (company) — CIK number for Phio Pharmaceuticals Corp.
- 0001437749-26-011761 (company) — SEC Accession Number for the filing
- April 8, 2026 (date) — Filing Date and Period of Report
FAQ
What type of material definitive agreement did Phio Pharmaceuticals Corp. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into.
When was the 8-K filing accepted by the SEC?
The 8-K filing was accepted on April 8, 2026, at 16:15:54.
What are the main items reported in this 8-K filing?
The main items reported are Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
Where is Phio Pharmaceuticals Corp. located?
Phio Pharmaceuticals Corp. is located at 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406.
What is the CIK number for Phio Pharmaceuticals Corp.?
The CIK number for Phio Pharmaceuticals Corp. is 0001533040.
From the Filing
EDGAR Filing Documents for 0001437749-26-011761 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001437749-26-011761 Filing Date 2026-04-08 Accepted 2026-04-08 16:15:54 Documents 15 Period of Report 2026-04-08 Items Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 FORM 8-K phio20260402_8k.htm iXBRL 8-K 29874 2 EXHIBIT 5.1 ex_942764.htm EX-5.1 8649 3 EXHIBIT 10.1 ex_942765.htm EX-10.1 192595 8 ex_942764img001.jpg GRAPHIC 2618 Complete submission text file 0001437749-26-011761.txt 423402 Data Files Seq Description Document Type Size 4 XBRL TAXONOMY EXTENSION SCHEMA phio-20260408.xsd EX-101.SCH 3578 5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE phio-20260408_def.xml EX-101.DEF 11806 6 XBRL TAXONOMY EXTENSION LABEL LINKBASE phio-20260408_lab.xml EX-101.LAB 15857 7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE phio-20260408_pre.xml EX-101.PRE 12021 18 EXTRACTED XBRL INSTANCE DOCUMENT phio20260402_8k_htm.xml XML 2960 Mailing Address 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406 Business Address 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406 (508) 767-3861 Phio Pharmaceuticals Corp. (Filer) CIK : 0001533040 (see all company filings) EIN. : 453215903 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 26848312 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)